New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 6, 2014
08:14 EDTGHDXGenomic Health's Oncotype DX for prostate cancer shows positive results
Genomic Health announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research demonstrating that the Oncotype DX Genomic Prostate Score predicts multiple clinical endpoints related to disease aggressiveness in men with low- and intermediate-risk prostate cancer. This study validated the Oncotype DX prostate cancer test as a predictor of biochemical recurrence, a rise in prostate-specific antigen following surgery, which is a measure of longer-term outcomes for aggressive disease. Additional endpoints of this prostate cancer study include the development of metastatic disease and outcomes in African-American patients.
News For GHDX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
December 19, 2014
10:17 EDTGHDXOn The Fly: Analyst Initiation Summary
Subscribe for More Information
07:15 EDTGHDXGenomic Health initiated with a Market Perform at Wells Fargo
Price target range $33-$35.
December 18, 2014
08:05 EDTGHDXGenomic Health apoints Patrick F. Terry as Chief Commercial Officer
Claritas Genomics appointed Patrick F. Terry to the role of Chief Commercial Officer. Terry has been involved in shepherding multiple biotechnology products through commercial development to clinical delivery.
December 10, 2014
08:06 EDTGHDXGenomic Health presents first results of Oncotype DX breast cancer test
Subscribe for More Information
December 9, 2014
09:03 EDTGHDXGenomic Health advances development of novel liquid biopsy-based cancer tests
Subscribe for More Information
December 8, 2014
07:26 EDTGHDXLeerink to hold a tour
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use